Repare Therapeutics to Present Phase 1/2 Cancer Trial Data at Barcelona Conference
Repare Therapeutics to Present Phase 1/2 Cancer Trial Data at Barcelona Conference
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1/2 TRESR clinical trial during an oral presentation on September 14 at the European Society for Medical Oncology Congress (ESMO), held in Barcelona, Spain.
愛文思控股公司（「Repare」 或 「公司」）（NASDAQ：RPTX）是一家領先的臨床前期精準腫瘤醫療公司，今天宣佈該公司將在9月14日的歐洲醫學腫瘤學學會（ESMO）巴塞羅那會議上通過口頭報告分享其正在進行的第一、二階段TRESR臨床試驗的模塊1中的新數據。
TRESR (NCT04497116) is a first-in-human, multi-center, open-label Phase 1/2 dose-escalation and expansion study designed to establish the recommended Phase 2 dose (RP2D) and schedule. The study evaluated safety, pharmacokinetics and identify preliminary anti-tumor activity associated with camonsertib monotherapy in patients with solid tumors (Module 1).
TRESR (NCT04497116) 是一項首次應用於人類的、多中心的開放性一、二階段遞增劑量和擴大研究，旨在確定推薦的二階段劑量（RP2D）和劑量方案。該研究評估了單藥卡蒙塞替治療固體腫瘤患者的安全性、藥動學，並確定了與之相關的初步抗腫瘤活性（模塊1）。
譯文內容由第三人軟體翻譯。
